Literature DB >> 21610308

Lower extremity soft tissue reconstruction with free flap based on subscapular artery.

Semra Karşıdağ1, Arzu Akçal, Gürsel Turgut, Kemal Uğurlu, Lütfü Baş.   

Abstract

OBJECTIVES: The purpose of our study was to evaluate the results of the reconstruction of the lower extremity defects with free flaps based on the subscapular artery.
METHODS: Between January, 1998 and December, 2008, 51 patients (mean age 26 years; 16 female and 35 male) presenting with a lower extremity defect underwent a reconstructive surgery with flaps based on the subscapular vascular system. Thirty-seven percent of the defects were located in the crus, 19% in the sole, 16% in the heel, and 14% in the dorsum of the foot. Eighty and a half percent of the patients had traffic-accident-related and 13.5% had burn-related tissue defects.
RESULTS: Fifty-three percent of the patients presenting with lower extremity defects underwent reconstruction with latissimus dorsi muscle flaps, 21% with free serratus muscle and/or fascia flaps, 14% with free parascapular fasciocutaneous flaps, and 12% with free combined latissimus muscle and serratus muscle and/or fascia flaps. Anastomoses of 80% of the patients were performed on their posterior tibial artery and accompanying veins and/or foot dorsal veins. End-to-end anastomosis was performed on 14 patients, while 35 patients received end-to-side anastomosis. Six patients were treated with cross free flaps, of which 4 received cross latissimus, 1 cross serratus, and 1 cross combined serratus and latissimus flaps. End-to-side anastomoses were performed on these patients on the cross-leg tibialis posterior artery. The cross-leg anastomosis was freed 4 weeks later. In the early period, venous occlusion was observed in 4 patients and arterial and venous occlusion was present in 1 patient. New anastomoses were performed in these patients. Partial necrosis was observed in 2 patients. The average follow-up period was 61 months. Pressure-related late ulcerative lesions developed in 4 patients. The lesions of these patients were repaired by debridement and primary suturing or partial thickness skin grafts.
CONCLUSION: The subscapular vascular system based flaps have an optimal vascularity once they are prepared with adequate pedicles, causing minimal donor site morbidity. These flaps are a safe and effective alternative in lower extremity reconstruction. On the other hand, in the absence of appropriate recipient vessels, single or combined cross-leg free flaps may provide successful repair.

Entities:  

Mesh:

Year:  2011        PMID: 21610308     DOI: 10.3944/AOTT.2011.2261

Source DB:  PubMed          Journal:  Acta Orthop Traumatol Turc        ISSN: 1017-995X            Impact factor:   1.511


  5 in total

Review 1.  Plastic Surgery Challenges in War Wounded I: Flap-Based Extremity Reconstruction.

Authors:  Jennifer M Sabino; Julia Slater; Ian L Valerio
Journal:  Adv Wound Care (New Rochelle)       Date:  2016-09-01       Impact factor: 4.730

2.  Flap decisions and options in soft tissue coverage of the lower limb.

Authors:  Daniel J Jordan; Marco Malahias; Sandip Hindocha; Ali Juma
Journal:  Open Orthop J       Date:  2014-10-31

3.  A retrospective analysis of latissimus dorsi-serratus anterior chimeric flap reconstruction in 47 patients with extensive lower extremity trauma.

Authors:  Ravi Kumar Mahajan; Krishnan Srinivasan; Abhiskek Bhamre; Mahipal Singh; Prakash Kumar; Ankush Tambotra
Journal:  Indian J Plast Surg       Date:  2018 Jan-Apr

4.  Thoracodorsal artery perforator fasciocutaneous flap: A versatile alternative for coverage of various soft tissue defects.

Authors:  Celalettin Sever; Fatih Uygur; Yalcin Kulahci; Huseyin Karagoz; Cihan Sahin
Journal:  Indian J Plast Surg       Date:  2012-09

5.  Reconstruction of complex shallow defects of the extremities with free serratus musculofascial flap

Authors:  Hakan Çinal; Ensar Zafer Barin; Murat Kara; Kerem Yilmaz; Harun Karaduman; Ihtişam Zafer Cengiz; Önder Tan
Journal:  Turk J Med Sci       Date:  2020-02-13       Impact factor: 0.973

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.